Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial

Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic colorectal cancer. We aimed to establish whether SOX plus bevacizumab is non-inferior to mFOLFOX6 (modified regimen of leucovorin, fluorouracil, and oxaliplatin)...

Full description

Saved in:
Bibliographic Details
Published in:The lancet oncology Vol. 14; no. 13; pp. 1278 - 1286
Main Authors: Yamada, Yasuhide, Takahari, Daisuke, Matsumoto, Hiroshi, Baba, Hideo, Nakamura, Masato, Yoshida, Kazuhiro, Yoshida, Motoki, Iwamoto, Shigeyoshi, Shimada, Ken, Komatsu, Yoshito, Sasaki, Yasutsuna, Satoh, Taroh, Takahashi, Keiichi, Mishima, Hideyuki, Muro, Kei, Watanabe, Masahiko, Sakata, Yuh, Morita, Satoshi, Shimada, Yasuhiro, Sugihara, Kenichi
Format: Journal Article
Language:English
Published: England Elsevier Ltd 01.12.2013
Elsevier Limited
Subjects:
ISSN:1470-2045, 1474-5488, 1474-5488
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first